277 related articles for article (PubMed ID: 19755607)
1. Pediatric FDG PET/CT: Physiologic uptake, normal variants, and benign conditions [corrected].
Bestic JM; Peterson JJ; Bancroft LW
Radiographics; 2009; 29(5):1487-500. PubMed ID: 19755607
[TBL] [Abstract][Full Text] [Related]
2. F-18-FDG PET-CT in children and young adults with Ewing sarcoma diagnosed in Norway during 2005-2012: a national population-based study.
Johnsen B; Boye K; Rosendahl K; Biermann M; Trovik C; Aukland SM
Clin Physiol Funct Imaging; 2016 Nov; 36(6):441-446. PubMed ID: 26039107
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.
Völker T; Denecke T; Steffen I; Misch D; Schönberger S; Plotkin M; Ruf J; Furth C; Stöver B; Hautzel H; Henze G; Amthauer H
J Clin Oncol; 2007 Dec; 25(34):5435-41. PubMed ID: 18048826
[TBL] [Abstract][Full Text] [Related]
4. The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.
Palmerini E; Colangeli M; Nanni C; Fanti S; Marchesi E; Paioli A; Picci P; Cambioli S; Donati D; Cevolani L; De Paolis M; Gambarotti M; Ferrari S
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):215-223. PubMed ID: 27645694
[TBL] [Abstract][Full Text] [Related]
5. F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors.
Peterson JJ
Semin Musculoskelet Radiol; 2007 Sep; 11(3):246-60. PubMed ID: 18260035
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma.
Newman EN; Jones RL; Hawkins DS
Pediatr Blood Cancer; 2013 Jul; 60(7):1113-7. PubMed ID: 23192939
[TBL] [Abstract][Full Text] [Related]
7. Is methylene diphosphonate bone scan necessary for initial staging of Ewing sarcoma if 18F-FDG PET/CT is performed?
Ulaner GA; Magnan H; Healey JH; Weber WA; Meyers PA
AJR Am J Roentgenol; 2014 Apr; 202(4):859-67. PubMed ID: 24660717
[TBL] [Abstract][Full Text] [Related]
8. Invited commentary.
Lee ME
Radiographics; 2009; 29(5):1500-1; discussion 1501. PubMed ID: 19764110
[No Abstract] [Full Text] [Related]
9. Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma.
Raciborska A; Bilska K; Drabko K; Michalak E; Chaber R; Pogorzała M; Połczyńska K; Sobol G; Wieczorek M; Muszyńska-Rosłan K; Rychlowska-Pruszyńska M; Rodriguez-Galindo C; Dziuk M
Clin Transl Oncol; 2016 Feb; 18(2):189-95. PubMed ID: 26250765
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Accuracy of 18F-FDG PET/CT in the Staging and Assessment of Response to Chemotherapy in Children With Ewing Sarcoma.
Ruggiero A; Lanni V; Librizzi A; Maurizi P; Attinà G; Mastrangelo S; Giordano A; Riccardi R
J Pediatr Hematol Oncol; 2018 May; 40(4):277-284. PubMed ID: 29620679
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
12. Pediatric bone sarcoma: diagnostic performance of ¹⁸F-FDG PET/CT versus conventional imaging for initial staging and follow-up.
Quartuccio N; Fox J; Kuk D; Wexler LH; Baldari S; Cistaro A; Schöder H
AJR Am J Roentgenol; 2015 Jan; 204(1):153-60. PubMed ID: 25539251
[TBL] [Abstract][Full Text] [Related]
13. Can FDG-PET/CT replace blind bone marrow biopsy of the posterior iliac crest in Ewing sarcoma?
Kasalak Ö; Glaudemans AWJM; Overbosch J; Jutte PC; Kwee TC
Skeletal Radiol; 2018 Mar; 47(3):363-367. PubMed ID: 29124298
[TBL] [Abstract][Full Text] [Related]
14. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters.
Denecke T; Hundsdörfer P; Misch D; Steffen IG; Schönberger S; Furth C; Plotkin M; Ruf J; Hautzel H; Stöver B; Kluge R; Bierbach U; Otto S; Beck JF; Franzius C; Henze G; Amthauer H
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1842-53. PubMed ID: 20505933
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Prognostic Role of 18F-FDG PET/CT in Pediatric Ewing Sarcoma.
Albano D; Dondi F; Schumacher RF; D'Ippolito C; Porta F; Giubbini R; Bertagna F
J Pediatr Hematol Oncol; 2020 Mar; 42(2):e79-e86. PubMed ID: 31135716
[TBL] [Abstract][Full Text] [Related]
16. Post-treatment FDG PET/CT predicts progression-free survival in young patients with small round blue cell tumors: Ewing sarcoma and PNET.
Sobic Saranovic DP; Nikitovic M; Saponjski J; Grozdic Milojevic I; Paripovic L; Saranovic D; Beatovic S; Artiko VM
Eur J Radiol; 2020 Aug; 129():109076. PubMed ID: 32446127
[TBL] [Abstract][Full Text] [Related]
17. Estimated cumulative radiation dose received by diagnostic imaging during staging and treatment of operable Ewing sarcoma 2005-2012.
Johnsen B; Fasmer KE; Boye K; Rosendahl K; Trovik C; Biermann M; Aukland SM
Pediatr Radiol; 2017 Jan; 47(1):82-88. PubMed ID: 27815616
[TBL] [Abstract][Full Text] [Related]
18. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
[TBL] [Abstract][Full Text] [Related]
19. Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours.
Györke T; Zajic T; Lange A; Schäfer O; Moser E; Makó E; Brink I
Nucl Med Commun; 2006 Jan; 27(1):17-24. PubMed ID: 16340719
[TBL] [Abstract][Full Text] [Related]
20. FDG PET/CT versus CT, MR imaging, and 67Ga scintigraphy in the posttherapy evaluation of malignant lymphoma.
Okada M; Sato N; Ishii K; Matsumura K; Hosono M; Murakami T
Radiographics; 2010; 30(4):939-57. PubMed ID: 20631361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
